Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of bimekizumab in adults with moderate to severe chronic plaque psoriasis; results were posted in March 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Bimekizumab (bimekizumab)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2022-03-02